Evidence map›Paper›PMID 40277758›Full record

ArticleCurrent oncology (Toronto, Ont.)2025

Merkel-Cell Carcinoma: Local Recurrence Rate Versus Radiation Dose Study from a 949-Patient Database.

Patricia Tai, Michael Veness, Vimal H Prajapati, Aoife Jones Thachuthara, Jidong Lian, Avi Assouline, Edward Yu, Kurian Joseph

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Patricia TaiDepartment of Oncology, University of Saskatchewan, Saskatoon, SK S7N 5A2, Canada.ORCID 0000-0001-7700-776X
Michael VenessDepartment of Oncology, University of Sydney, Sydney, NSW 2050, Australia.
Vimal H PrajapatiDepartment of Dermatology, University of Calgary, Calgary, AB T2N 1N4, Canada.
Aoife Jones ThachutharaDepartment of Medical Oncology, Cork University Hospital, T12 DC4A Cork, Ireland.
Jidong LianDepartment of Oncology, University of Toronto, Toronto, ON M5S 1A1, Canada.
Avi AssoulineDepartment of Radiation Oncology, Centre de Cancérologie de la Porte de Saint-Cloud (CCPSC), 92100 Boulogne-Billancourt, France.
Edward YuDepartment of Oncology, Western University, London, ON N6A 3K7, Canada.ORCID 0000-0002-2900-115X
Kurian JosephDepartment of Oncology, University of Alberta, Edmonton, AB T6G 2R3, Canada.ORCID 0000-0003-3514-2183

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

(1) Background: Knowledge regarding the optimal radiotherapy dose for Merkel-cell carcinoma (MCC) remains limited. (2) Methods: Following a PubMed search, equivalent doses in 2 Gy fractions (Gy2) were compared. (3) Results: Of the 949 patients, 939 were evaluable, with 728 (77.5%) cases localized to the primary site and 171 irradiated without chemotherapy. The overall local recurrence rate (LRR) was 23% (40/171). After definitive radiotherapy with EQD2 < 50 Gy2 versus ≥50 Gy2, the LRRs were 23.1% (3/13) and 12.5% a(1/8), respectively (

Indexed as

Carcinoma, Merkel CellNeoplasm Recurrence, LocalSkin NeoplasmsAdultAgedAged, 80 and overDatabases, FactualFemaleHumansMaleMiddle AgedRadiotherapy Dosagedatabaselocal recurrenceMerkel-cell carcinomapattern of spreadradiotherapy doseskin

Identifiers

PMID40277758
PMCPMC12026359

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.